SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-015034
Filing Date
2022-04-19
Accepted
2022-04-19 16:30:46
Documents
13
Period of Report
2022-04-15
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10036518_8k.htm   iXBRL 8-K 28139
2 EXHIBIT 16.1 brhc10036518_ex16-1.htm EX-16.1 2801
  Complete submission text file 0001140361-22-015034.txt   169917

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA btx-20220415.xsd EX-101.SCH 3929
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20220415_lab.xml EX-101.LAB 22544
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20220415_pre.xml EX-101.PRE 16047
7 EXTRACTED XBRL INSTANCE DOCUMENT brhc10036518_8k_htm.xml XML 4245
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 22835244
SIC: 2834 Pharmaceutical Preparations